Moody Aldrich Partners LLC Purchases Shares of 22,331 Blueprint Medicines Corporation (NASDAQ:BPMC)

Moody Aldrich Partners LLC bought a new position in shares of Blueprint Medicines Corporation (NASDAQ:BPMC - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 22,331 shares of the biotechnology company's stock, valued at approximately $1,977,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Principal Financial Group Inc. grew its position in shares of Blueprint Medicines by 46.6% in the fourth quarter. Principal Financial Group Inc. now owns 16,183 shares of the biotechnology company's stock valued at $1,411,000 after purchasing an additional 5,145 shares during the last quarter. Truist Financial Corp acquired a new stake in shares of Blueprint Medicines during the 4th quarter valued at $221,000. Bank of New York Mellon Corp raised its position in Blueprint Medicines by 2.4% during the 4th quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company's stock worth $26,465,000 after purchasing an additional 7,101 shares during the last quarter. Proficio Capital Partners LLC bought a new position in Blueprint Medicines during the 4th quarter worth $1,012,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Blueprint Medicines by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 604,397 shares of the biotechnology company's stock worth $52,716,000 after acquiring an additional 7,165 shares in the last quarter.

Blueprint Medicines Stock Up 0.1%

Shares of NASDAQ BPMC traded up $0.07 during mid-day trading on Friday, reaching $128.27. The company had a trading volume of 1,350,246 shares, compared to its average volume of 1,324,110. The company has a debt-to-equity ratio of 1.01, a quick ratio of 2.75 and a current ratio of 2.80. The stock has a market capitalization of $8.28 billion, a PE ratio of -51.93 and a beta of 0.89. Blueprint Medicines Corporation has a twelve month low of $73.04 and a twelve month high of $128.52. The stock's 50 day moving average is $113.55 and its 200-day moving average is $100.42.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). The company had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative net margin of 27.70% and a negative return on equity of 64.60%. The business's revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.40 EPS. As a group, equities analysts anticipate that Blueprint Medicines Corporation will post -1.28 earnings per share for the current fiscal year.

Insider Activity at Blueprint Medicines

In other news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $100.51, for a total transaction of $228,559.74. Following the completion of the transaction, the chief operating officer directly owned 64,718 shares in the company, valued at $6,504,806.18. This trade represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of Blueprint Medicines stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $101.14, for a total transaction of $505,700.00. Following the completion of the sale, the director directly owned 146,630 shares in the company, valued at approximately $14,830,158.20. This represents a 3.30% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,300 shares of company stock worth $1,249,453. Insiders own 4.21% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on BPMC shares. TD Cowen downgraded Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, June 3rd. Wells Fargo & Company lowered shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating and dropped their target price for the stock from $143.00 to $129.00 in a report on Tuesday, June 17th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $129.00 price target (down previously from $130.00) on shares of Blueprint Medicines in a research report on Monday, June 2nd. Guggenheim set a $132.00 price target on shares of Blueprint Medicines in a research note on Tuesday, June 3rd. Finally, Wolfe Research cut shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, June 3rd. Eighteen analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Blueprint Medicines presently has a consensus rating of "Hold" and a consensus price target of $128.06.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.